MedTrace Logo

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

NCT05779163 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-05-14

No results posted yet for this study

Summary

This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.

Conditions

  • Advanced Malignant Tumors

Interventions

DRUG

LBL-033 for Injection

Initial dose - MTD; Q2W; intravenous infusion

Sponsors & Collaborators

  • Nanjing Leads Biolabs Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • jihong liu · Sun Yat-Sen University Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-14
Primary Completion
2025-04-03
Completion
2025-04-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05779163 on ClinicalTrials.gov